We will review new data and standard of care for each disease state of prostate cancer. We will review low risk disease, intermediate risk, high risk, locally advanced, node positive, oligometastatic, post-operative and recurrent prostate cancer. We will also review new data in bladder and testicular cancers.
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, participants should be able to do the following:
- Treat all risk groups, including oligometastatic prostate cancer, with radiation when appropriate.
- Utilize androgen deprivation therapy with radiation for prostate cancer when appropriate.
- Hypofractionate radiation for prostate cancer when appropriate.
Rahul Tendulkar, MD, is employed by the Cleveland Clinic and receives compensation from Varian Medical Systems.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.